Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
P 1 (4)
P 2 (3)

Trial Status

Active Not Recruiting4
Unknown1
Not Yet Recruiting1
Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05446298Phase 2Active Not Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

NCT05858736Phase 1Active Not Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

NCT05527184Phase 1Active Not Recruiting

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05902988Phase 1Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT06084416Phase 1Active Not RecruitingPrimary

A Study of Sovilnesib in Subjects With Ovarian Cancer

NCT06161272Phase 2Unknown

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

NCT06063070Phase 2Not Yet Recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Showing all 7 trials

Research Network

Activity Timeline